Effervescent oral tablets in a sealed container

Effervescent oral tablets with controlled carbonate, organic acid, and cellulose ratios and sizes ensure a pleasant foaming sensation and stable storage without container swelling.

JP7594929B2Active Publication Date: 2024-12-05KAO CORP
View PDF 8 Cites 0 Cited by

Patent Information

Application Number
JP2021021601
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-05-15
Filing Date
2021-02-15
Publication Date
2024-12-05
Estimated Expiration
2041-02-15

AI Technical Summary

Technical Problem

Effervescent oral preparations containing high amounts of carbonate or organic acid can cause bitterness and react during storage, leading to container swelling, compromising storage stability.

Method used

Formulating effervescent oral tablets with a specific ratio of carbonate to organic acid and cellulose within certain ranges, ensuring a pleasant foaming sensation and high storage stability without bulging.

Benefits of technology

The tablets provide a pleasant foaming experience, good flavor, and maintain container integrity during storage by controlling the molar ratio and particle size of components.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007594929000001
    Figure 0007594929000001
  • Figure 0007594929000002
    Figure 0007594929000002
  • Figure 0007594929000003
    Figure 0007594929000003
Patent Text Reader

Abstract

To provide a foamable oral tablet packed in a sealed container with high storage stability which has satisfactory flavor and no swell when packing into a container while having high foaming property and comfortable foaming feel when ingested.SOLUTION: A foamable oral tablet packed in sealed container which contains the following components (A), (B) and (C): (A) 14 to 30 mass% of carbonate; (B) organic acid or salt thereof; and (C) 0.5 to 50 mass% of cellulose having the average particle diameter of 30 to 70 μm, in which a ratio between mole number(mol) of component (A) and mole number(mol) of acid radical of component (B) [mole number(mol) of (A) / mole number (mol) of acid radical of (B)] is 0.25 or more and 3.0 or less, and the content mass ratio [(A) / (C)] of component (A) with respect to component (C) is 0.5 or more.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to an effervescent oral tablet in a sealed container. [Background technology]

[0002] It is known that the effervescence of carbon dioxide gas promotes saliva secretion, enhances the effects of ingredients that act on the throat, and provides a pleasant feeling when taken due to the effervescence in the mouth.

[0003] For example, Patent Document 1 discloses a candy with good productivity and storage stability, which contains sugars and a combination of an organic acid and a carbonate or bicarbonate as effervescent ingredients, and in which the content of maltose in the sugars is 25% by weight or less. Patent Document 2 discloses an oligosaccharide supplement preparation in the form of an effervescent chewable tablet with good texture and stability, which contains oligosaccharides, an effervescent agent component, and a neutralizing agent component.

[0004] On the other hand, powdered cellulose with a large particle size, such as crystalline cellulose, is preferably used as a tablet excipient, binder, and disintegrant because it is tasteless, chemically inactive, and has excellent compression moldability and tableting properties. [Prior art documents] [Patent documents]

[0005] [Patent Document 1] JP 2004-16073 A [Patent Document 2] JP 2001-8666 A Summary of the Invention [Problem to be solved by the invention]

[0006] However, when an effervescent oral preparation contains a high content of effervescent ingredients such as carbonates or organic acids to increase the effervescent properties, the carbonates taste bitter, and a reaction between the carbonates and the acids proceeds during storage, causing the container to bulge when the effervescent oral preparation is sealed in the container. These problems, however, have not been given much attention up until now.

[0007] Therefore, the present invention relates to an effervescent oral tablet in a sealed container which has a high effervescent property, gives a pleasant effervescent feeling when taken, has a good flavor, does not bulge when sealed in the container, and has high storage stability. [Means for solving the problem]

[0008] As a result of extensive research, the present inventors have found that, even when a specific cellulose is used and a high carbonate content is used to enhance effervescence, by combining the cellulose with the carbonate at a ratio within a certain range and formulating the number of moles of carbonate in the formulation and the number of moles of acid groups in the organic acid within a certain range, it is possible to obtain an effervescent oral tablet in a sealed container which has a pleasant high effervescence in the mouth, melts easily in the mouth, has little bitterness due to the carbonate, and has high storage stability without swelling of the container.

[0009] The present invention comprises the following components (A), (B) and (C): (A) Carbonate 14-30% by mass (B) Organic acid or its salt (C) Cellulose having an average particle size of 30 to 70 μm: 0.5 to 50% by mass The present invention provides an effervescent oral tablet in a sealed container, which contains: a ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups (B)] is 0.25 or more and 3.0 or less; and a mass ratio of component (A) to component (C) [(A) / (C)] is 0.5 or more. Effect of the Invention

[0010] The effervescent oral tablet in a sealed container of the present invention has a pleasant high effervescent feeling in the mouth, good meltability in the mouth, and good flavor, does not swell when sealed in the container, and has excellent storage stability. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0011] The sealed container-packed effervescent oral tablet of the present invention contains a carbonate as component (A). Examples of carbonates include sodium carbonate, sodium bicarbonate, potassium carbonate, potassium bicarbonate, ammonium carbonate, and sodium sesquicarbonate. These can be used alone or in combination of two or more. From the viewpoint of achieving high effervescence and a pleasant effervescent sensation when taken, component (A) is preferably one or more selected from the group consisting of sodium carbonate, sodium bicarbonate, and potassium carbonate, and more preferably sodium bicarbonate.

[0012] The content of component (A) in the effervescent oral tablet of the present invention is 14 to 30% by mass. By including component (A) in such a specific amount, it is possible to realize high effervescence and a comfortable effervescent feeling when taken, while also having high storage stability without swelling of the container. The content of component (A) in the effervescent oral tablet of the present invention is 14% by mass or more, preferably 15% by mass or more, more preferably 18% by mass or more, from the viewpoint of realizing a pleasant effervescent feeling in the mouth, and is 30% by mass or less, preferably 26% by mass or less, more preferably 22% by mass or less, from the viewpoint of suppressing the swelling of the container. The content of component (A) in the effervescent oral tablet of the present invention is 14 to 30% by mass, preferably 15 to 26% by mass, more preferably 18 to 26% by mass, and even more preferably 18 to 22% by mass. In this specification, the content of component (A) is expressed as a carbonic acid equivalent value.

[0013] The number of moles (mmol / 100 g) of component (A) in the effervescent oral tablet of the present invention refers to the number of moles converted into carbonate ions or bicarbonate ions in component (A). The molar number (mmol / 100g) of component (A) in the effervescent oral tablet of the present invention is preferably 160mmol / 100g or more, more preferably 175mmol / 100g or more, and even more preferably 210mmol / 100g or more from the viewpoint of realizing high effervescence and a pleasant effervescent feeling when taken, and is preferably 360mmol / 100g or less, more preferably 300mmol / 100g or less, and even more preferably 265mmol / 100g or less from the viewpoint of suppressing swelling of the container. The molar number (mmol / 100g) of component (A) in the effervescent oral tablet of the present invention is preferably 160 to 360mmol / 100g, more preferably 175 to 300mmol / 100g, even more preferably 210 to 300mmol / 100g, and even more preferably 210 to 265mmol / 100g.

[0014] The effervescent oral tablet in a sealed container of the present invention contains an organic acid or a salt thereof as component (B). The organic acid or the salt thereof is not particularly limited, but is preferably one or more selected from hydroxycarboxylic acids, dicarboxylic acids, ascorbic acid, and salts thereof. Examples of hydroxycarboxylic acids include lactic acid, citric acid, isocitric acid, malic acid, tartaric acid, gluconic acid, and quinic acid. Examples of dicarboxylic acids include oxalic acid, malonic acid, succinic acid, glutaric acid, adipic acid, fumaric acid, and maleic acid. Ascorbic acid includes the stereoisomers L-ascorbic acid and erythorbic acid. The salt is preferably an alkali metal salt, more preferably one selected from a sodium salt and a potassium salt, and even more preferably a sodium salt. Among these, from the viewpoint of achieving high foaming and a pleasant fizzing sensation upon ingestion, preferred are one or more selected from hydroxycarboxylic acids, ascorbic acid and salts thereof, more preferred are one or more selected from citric acid, malic acid, tartaric acid, ascorbic acid and salts thereof, and even more preferred is citric acid.

[0015] The content of component (B) in the effervescent oral tablet of the present invention is preferably 5% by mass or more, more preferably 10% by mass or more, from the viewpoint of achieving high effervescence and a pleasant effervescent feeling when taken, and is preferably 45% by mass or less, more preferably 40% by mass or less, and even more preferably 25% by mass or less, from the viewpoint of reducing discomfort of the mucosa when taken. The content of component (B) in the effervescent oral tablet is preferably 5 to 45% by mass, more preferably 5 to 40% by mass, and even more preferably 10 to 25% by mass. In this specification, the content of component (B) is expressed in terms of organic acid.

[0016] In the effervescent oral tablet of the present invention, the molar number of the acid group of component (B) is preferably 50 mmol / 100 g or more, more preferably 150 mmol / 100 g or more, from the viewpoint of realizing high effervescence and a comfortable effervescent feeling when taken, and is preferably 600 mmol / 100 g or less, more preferably 360 mmol / 100 g or less, from the viewpoint of reducing discomfort of the mucous membrane when taken. The molar number of the acid group of component (B) in the effervescent oral tablet is preferably 50 to 600 mmol / 100 g, more preferably 150 to 360 mmol / 100 g. When ascorbic acid is used as component (B) in the present invention, the molar number of the acid group is calculated as an organic acid having one acid group.

[0017] In the effervescent oral tablet of the present invention, the ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (mol) of component (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups (B)] is 0.25 to 3.0. By setting the number of moles of carbonate to the number of moles of acid groups of an organic acid or its salt at such a specific ratio, it is possible to realize a high effervescence and a comfortable effervescent feeling when taken, and also to reduce discomfort in the mucous membrane. The ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups (B)] is 0.25 or more, preferably 0.5 or more, more preferably 0.8 or more, from the viewpoint of realizing a high foaming and comfortable foaming feeling when taken, and from the viewpoint of improving the melting in the mouth when taken, and is 3.0 or less, preferably 1.5 or less, more preferably 1.0 or less, from the viewpoint of suppressing the swelling of the container. The ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups (B)] is 0.25 to 3.0, preferably 0.5 to 1.5, more preferably 0.8 to 1.0.

[0018] The effervescent oral tablet of the present invention has a mass ratio of component (A) to component (B) [(A) / (B)] of preferably 0.35 or more, more preferably 0.70 or more, and even more preferably 1.1 or more, from the viewpoint of achieving high effervescence and a pleasant effervescent feeling when taken, and from the viewpoint of improving the melting in the mouth when taken, and from the viewpoint of suppressing swelling of the container, the mass ratio is preferably 4.0 or less, more preferably 2.0 or less, and even more preferably 1.4 or less.

[0019] The effervescent oral tablet in a sealed container of the present invention contains cellulose having an average particle size of 30 to 70 μm as component (C). Unless otherwise specified, the term "cellulose" in the present invention is used to mean cellulose based on the definition generally accepted by those skilled in the art, that is, a general term for polysaccharides having a structure in which D-glucopyranose is linked by β1→4 bonds, as well as crystalline cellulose, fine fibrous cellulose, and mixtures thereof, which will be described later. Examples of commonly available cellulose include ordinary cellulose in powder form (hereinafter referred to as "powdered cellulose"), such as cellulose flock, and ordinary cellulose in crystalline form (hereinafter referred to as "crystalline cellulose").

[0020] Powdered cellulose is obtained by treating α-cellulose obtained as pulp from fibrous plants, purifying it, and mechanically pulverizing it. For example, it corresponds to the powdered cellulose described in the Japanese Pharmacopoeia, 15th Edition (published by Hirokawa Shoten). The average degree of polymerization of the powdered cellulose is specified to be greater than 440. This value can be measured according to the reduced specific viscosity method using a copper ethylenediamine solution described in the Verification Test (3) of the Japanese Pharmacopoeia, 15th Edition (published by Hirokawa Shoten). An example of the powdered cellulose is KC Flock W-100G manufactured by Nippon Paper Industries Co., Ltd.

[0021] Crystalline cellulose is a product obtained by partially depolymerizing α-cellulose obtained as pulp from fibrous plants with an acid and purifying it. For example, it corresponds to the crystalline cellulose described in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten). The average degree of polymerization of crystalline cellulose is preferably 350 or less. This value can be measured according to the reduced specific viscosity method using a copper ethylenediamine solution described in the 15th Revised Japanese Pharmacopoeia Commentary (published by Hirokawa Shoten), confirmation test for crystalline cellulose (3). As the crystalline cellulose, for example, the CEOLUS ST series by Asahi Kasei Corporation can be mentioned. In the present invention, either powdered cellulose or crystalline cellulose can be used, or the two can be used in combination. In addition, depending on the pharmaceutical aspects of each country, only one of them can be used.

[0022] The average particle size of the cellulose in the present invention is 30 to 70 μm. If the average particle size of the cellulose is small, the bitterness reducing effect of the component (A) is reduced, and the formulation is restricted because it is necessary to mask it with other components such as flavors. On the other hand, if the average particle size of the cellulose is 30 μm or more, the degree of freedom of the formulation increases. The average particle size of cellulose is 30 μm or more, preferably 35 μm or more, more preferably 40 μm or more, from the viewpoint of reducing the bitterness of component (A) and increasing the freedom of formulation, and is 70 μm or less, preferably 60 μm or less, more preferably 55 μm or less, from the viewpoint of improving melting in the mouth when taken, realizing a high foaming and comfortable foaming feeling when taken, and reducing the bitterness of component (A).The average particle size of cellulose is 30 to 70 μm, preferably 35 to 60 μm, more preferably 40 to 55 μm. Here, the average particle size of cellulose in the present invention means the volume median particle size (D50). The volume median particle size (D50) in the present invention means the particle size at which the cumulative volume frequency calculated by volume fraction is 50% when calculated from the smallest particle size. The average particle size can be measured using a digital image analyzer (CAMSIZER manufactured by Microtrack Bell Co., Ltd.).

[0023] In the present invention, the bulk density value of the cellulose is preferably 0.1 to 0.8 g / cm from the viewpoint of improving the melting in the mouth when taken and from the viewpoint of realizing a high foaming rate and a comfortable foaming feeling when taken. 3 , more preferably 0.11 to 0.3 g / cm 3 As an example, the bulk density value of Ceolus® ST-100 (Asahi Kasei Corporation) is 0.12 g / cm 3 It is.

[0024] The cellulose in the present invention may be in the form of fine particles. The particle shape of cellulose can be defined by the L / D ratio described below. The L / D ratio of cellulose is the ratio of the major axis (L) to the minor axis (D), where the maximum diameter of cellulose in a powdery, particulate, or crystalline form is the diameter (L) (length of the major axis), and the maximum diameter perpendicular to the diameter (L) is the minor axis (D) (length of the minor axis), and can be determined by measuring the major axis (L) and minor axis (D) through microscopic observation using a scanning electron microscope. For example, the target cellulose is sieved through a JIS standard 75 μm sieve, and the sieved particles are observed using a scanning electron microscope (FlexSEM, Hitachi, Ltd.) at an accelerating voltage of 5 KV and a magnification of 3,000 times. From the obtained image, the long diameter (L) and short diameter (D) of 50 particles randomly selected are measured, and L / D can be calculated from the average values ​​(average long diameter (L) and average short diameter (D)). From the viewpoint of reducing the bitterness of component (A), the L / D of cellulose is preferably 2.4 or more, more preferably 2.7 or more, and even more preferably 3.0 or more, and from the viewpoint of improving the melting in the mouth when taken and realizing a high foaming and comfortable foaming feeling when taken, it is preferably 4.0 or less, more preferably 3.8 or less, and even more preferably 3.6 or less. The L / D of cellulose is preferably 2.4 to 4.0, more preferably 2.7 to 3.8, and even more preferably 3.0 to 3.6.

[0025] The content of component (C) in the effervescent oral tablet of the present invention is 0.5% by mass or more, preferably 1.5% by mass or more, more preferably 2.5% by mass or more, and even more preferably 4.0% by mass or more, from the viewpoint of reducing the bitterness of component (A), and from the viewpoint of improving the melting in the mouth when taken and realizing a high foaming and comfortable effervescent feeling when taken, it is 50% by mass or less, preferably 45% by mass or less, more preferably 25% by mass or less, and even more preferably 20% by mass or less. The content of component (C) in the effervescent oral tablet of the present invention is 0.5 to 50% by mass, preferably 1.5 to 45% by mass, more preferably 2.5 to 25% by mass, and even more preferably 4.0 to 20% by mass.

[0026] The mass ratio of component (A) to component (C) in the effervescent oral tablet of the present invention [(A) / (C)] is 0.5 or more, preferably 0.8 or more, more preferably 1.2 or more, from the viewpoint of improving the melting in the mouth when taken and from the viewpoint of realizing a high foaming and comfortable effervescent feeling when taken, and is preferably 15 or less, more preferably 11 or less, and even more preferably 4.5 or less, from the viewpoint of reducing the bitterness of component (A) and suppressing the swelling of the container. The mass ratio of component (A) to component (C) in the effervescent oral tablet of the present invention [(A) / (C)] is 0.5 or more, preferably 0.5 to 15, more preferably 0.8 to 11, and even more preferably 1.2 to 4.5.

[0027] The mass ratio of component (B) to component (C) in the effervescent oral tablet of the present invention [(B) / (C)] is preferably 0.3 or more, more preferably 0.7 or more, and even more preferably 0.9 or more, from the viewpoint of improving the melting in the mouth when taken and from the viewpoint of realizing a high foaming and comfortable effervescent feeling when taken, and is preferably 10 or less, more preferably 7 or less, and even more preferably 3.5 or less, from the viewpoint of reducing the bitterness of component (A). The mass ratio of component (B) to component (C) in the effervescent oral tablet of the present invention [(B) / (C)] is preferably 0.3 to 10, more preferably 0.7 to 7, and even more preferably 0.9 to 3.5.

[0028] The effervescent oral tablet of the present invention may contain additives other than components (A), (B), and (C) and, if necessary, an acceptable carrier, within the scope of not impairing the effects of the present invention. In the effervescent oral tablet of the present invention, it is preferable to use components with low hygroscopicity as the components other than components (A), (B), and (C) from the viewpoints of preventing unnecessary moisture absorption by the tablet, suppressing swelling of the container, and improving the melting property when taken in the mouth.

[0029] The additives are not particularly limited, and examples thereof include sweeteners, vitamins, minerals, extracts, acidulants other than component (B), flavorings, coloring agents, preservatives, etc. The content of the additives can be appropriately set within a range that does not impair the object of the present invention.

[0030] Examples of the carrier include excipients (disaccharides such as sucrose, lactose, maltose, trehalose, and palatinose, sugar alcohols such as maltitol, xylitol, erythritol, sorbitol, and reduced palatinose); binders (e.g., hydroxypropylmethylcellulose, hydroxypropylcellulose, gelatin, pregelatinized starch, polyvinylpyrrolidone, polyvinyl alcohol, pullulan, methylcellulose, and hardened oil); disintegrants (e.g., carmellose, carmellose calcium, croscarmellose sodium, crospovidone, corn starch, and low-substituted hydroxypropylcellulose); lubricants (e.g., calcium stearate, magnesium stearate, sucrose fatty acid esters, sodium stearyl fumarate, talc, and silicon dioxide); flavoring agents (e.g., stevia, menthol, and aspartame); and carriers such as agar, light anhydrous silicic acid, calcium hydrogen phosphate, fillers, surfactants, dispersants, buffers, and diluents. The content of the carrier can be appropriately set within a range that does not impair the object of the present invention.

[0031] In particular, the effervescent oral tablet of the present invention preferably contains a sugar alcohol from the viewpoint of suppressing swelling of the container. The sugar alcohol is preferably maltitol. The sugar alcohol may be either anhydrous or hydrated.

[0032] The sugar alcohol content in the effervescent oral tablet of the present invention is preferably 10% by mass or more, more preferably 20% by mass or more, and even more preferably 30% by mass or more from the viewpoint of suppressing swelling of the container, and is preferably 85% by mass or less, more preferably 80% by mass or less, and even more preferably 65% ​​by mass or less from the viewpoint of achieving high effervescence and a pleasant effervescent feeling when taken. The sugar alcohol content in the effervescent oral tablet is preferably 10 to 85% by mass, more preferably 20 to 80% by mass, and even more preferably 30 to 65% by mass.

[0033] HPLC can be used to quantify sugar alcohols. For example, analysis can be performed using an amino column and differential refractometry ("Dietary Fiber Basics and Applications", Supervised by the Japanese Society of Dietary Fiber, Edited by the Editorial Committee of the Japanese Society of Dietary Fiber and others, Author: Seiichiro Aoki, Publisher: Daiichi Publishing Co., Ltd., Release date: October 2008).

[0034] It is preferable that the effervescent oral tablet of the present invention contains a limited amount of oligosaccharides from the viewpoints of preventing unnecessary moisture absorption by the tablet, realizing high effervescence that provides a pleasant effervescent sensation when taken, and suppressing swelling of the container.

[0035] Here, limiting the content of oligosaccharides means that the oligosaccharide content in the effervescent oral tablet of the present invention is preferably 10% by mass or less, more preferably 5% by mass or less, even more preferably 1% by mass or less, and even more preferably substantially none.

[0036] In the present invention, the sealed container for enclosing the effervescent oral tablet is preferably an air-impermeable container, particularly a carbon dioxide-impermeable container, and may be a packaging container made of various plastics laminated with metals such as aluminum, a packaging container in which aluminum, silica, etc. are vapor-deposited, or a container made of metal, glass, etc. Here, the term "carbon dioxide-impermeable" refers to a carbon dioxide permeability of 50 cc / m 2·day·atm (ASTD-1434) or less. By sealing a container made of such a material, it is possible to seal the carbon dioxide gas so that it does not leak.

[0037] The form of the effervescent oral tablet of the present invention is preferably a troche tablet, which generates carbon dioxide gas in the presence of moisture such as saliva in the mouth, from the viewpoint of realizing a high degree of effervescence that provides a pleasant effervescent feeling when taken and from the viewpoint of suppressing swelling of the container.

[0038] To produce the effervescent oral tablet of the present invention, in addition to the components (A) to (C), additives that are added as necessary are mixed, and the mixture is directly compressed and molded using a tableting machine as a raw powder, or the mixture is granulated using a dry granulation method, a wet granulation method, or the like, and then the granulated product is compressed and molded using a tableting machine. As the tableting machine, a commonly used one such as a rotary tableting machine or a single-shot tableting machine can be used. From the viewpoint of maintaining the hardness of the molded product, the compression molding pressure during tableting is preferably about 10 to 30 MPa. In order to produce the effervescent oral tablet of the present invention at a lower compression molding pressure, it is preferable to use crystalline cellulose. In addition, the tablet hardness is preferably a hardness that can withstand transportation, storage, etc., and specifically, about 10N to 200N is preferable. In order to achieve the above hardness with a small amount of binder, it is preferable to use crystalline cellulose. The shape of the tablet may be various irregular shapes such as circular, elliptical, oval, rectangular, etc., but is preferably circular from the viewpoint of ingestibility. In the case of circular tablets, the diameter is preferably 3 to 30 mm, more preferably 10 to 20 mm, from the viewpoint of ingestibility. Moreover, the tablet preferably weighs 0.1 to 6 g, more preferably 0.3 to 3 g per preparation, from the viewpoint of simplicity and effectiveness.

[0039] The thus obtained effervescent tablet for oral administration is then sealed in the above-mentioned sealed container to obtain the effervescent tablet for oral administration in the sealed container of the present invention.

[0040] In relation to the above-mentioned embodiment, the present invention further discloses the following embodiments. <1> The following components (A), (B) and (C): (A) Carbonate 14-30% by mass (B) Organic acid or its salt (C) Cellulose having an average particle size of 30 to 70 μm: 0.5 to 50% by mass wherein the ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups of component (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups of (B)] is 0.25 or more and 3.0 or less, and the mass ratio of component (A) to component (C) [(A) / (C)] is 0.5 or more.

[0041] <2> The content of component (A) is 14% by mass or more, preferably 15% by mass or more, more preferably 18% by mass or more, and is 30% by mass or less, preferably 26% by mass or less, more preferably 22% by mass or less, and is 14 to 30% by mass, preferably 15 to 26% by mass, more preferably 18 to 26% by mass, and even more preferably 18 to 22% by mass. <1> 2. An effervescent oral tablet according to claim 1 in a sealed container. <3> Component (B) preferably contains one or more selected from hydroxycarboxylic acids, ascorbic acid, and salts thereof, more preferably contains one or more selected from citric acid, malic acid, tartaric acid, ascorbic acid, and salts thereof, and further preferably contains citric acid. <1> or <2> 2. An effervescent oral tablet according to claim 1 in a sealed container. <4> The ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (mol) of component (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups of (B)] is 0.25 or more, preferably 0.5 or more, more preferably 0.8 or more, and is 3.0 or less, preferably 1.5 or less, more preferably 1.0 or less, and is 0.25 to 3.0, preferably 0.5 to 1.5, more preferably 0.8 to 1.0. <1> ~ <3> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <5> The average particle size of the cellulose is 30 μm or more, preferably 35 μm or more, more preferably 40 μm or more, and is 70 μm or less, preferably 60 μm or less, more preferably 55 μm or less, and is 30 to 70 μm, preferably 35 to 60 μm, more preferably 40 to 55 μm. <1> ~ <4> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <6> The L / D of the cellulose is preferably 2.4 or more, more preferably 2.7 or more, and even more preferably 3.0 or more, and is preferably 4.0 or less, more preferably 3.8 or less, and even more preferably 3.6 or less, and is preferably 2.4 to 4.0, more preferably 2.7 to 3.8, and even more preferably 3.0 to 3.6. <1> ~ <5> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <7> The content of (C) is 0.5% by mass or more, preferably 1.5% by mass or more, more preferably 2.5% by mass or more, and even more preferably 4.0% by mass or more, and is 50% by mass or less, preferably 45% by mass or less, more preferably 25% by mass or less, and even more preferably 20% by mass or less, and is 0.5 to 50% by mass, preferably 1.5 to 45% by mass, more preferably 2.5 to 25% by mass, and even more preferably 4.0 to 20% by mass. <1> ~ <6> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <8> The content mass ratio of component (A) to component (C) [(A) / (C)] is 0.5 or more, preferably 0.8 or more, more preferably 1.2 or more, and is preferably 15 or less, more preferably 11 or less, even more preferably 4.5 or less, and is preferably 0.5 to 15, more preferably 0.8 to 11, even more preferably 1.2 to 4.5. <1> ~ <7> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <9> The mass ratio of component (B) to component (C) [(B) / (C)] is preferably 0.3 or more, more preferably 0.7 or more, and even more preferably 0.9 or more, and is preferably 10 or less, more preferably 7 or less, and even more preferably 3.5 or less, and is preferably 0.3 to 10, more preferably 0.7 to 7, and even more preferably 0.9 to 3.5. <1> ~ <8> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <10> Further, it preferably contains a sugar alcohol, more preferably maltitol. <1> ~ <9> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <11> The content of oligosaccharides is preferably 10% by mass or less, more preferably 5% by mass or less, even more preferably 1% by mass or less, and even more preferably substantially free of oligosaccharides. <1> ~ <10> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. <12> Preferably it is a lozenge tablet. <1> ~ <11> 2. The effervescent oral tablet according to claim 1, wherein the tablet is sealed in a container. EXAMPLES

[0042] [Carbonate analysis] The method for analyzing the carbonate content in effervescent oral tablets is as follows. 0.1-0.2 g of effervescent oral tablets were taken, 10 mL of water and 2 mL of 50% phosphoric acid were added, and the tablets were sealed. After ultrasonic treatment for 10 minutes, the tablets were left for 1 hour, and the headspace gas was subjected to gas chromatography to determine the amount of CO2, which was calculated from the amount of CO2 generated. <Gas chromatograph operating conditions> Model: GC-14B, Shimadzu Corporation Detector:TCD Column: Chromosorb 101, 80-100 mesh Glass tube, φ3.2mm×2m Temperature: Column 50℃, injection port and detector 100℃ Cell current 75mA Gas pressure: Helium (carrier gas) 100kPa Injection volume: Headspace gas 0.2mL

[0043] [Analysis of organic acids] The method for analyzing the content of organic acids in effervescent oral tablets is as follows. 1 g of effervescent oral tablets were taken, 20 mL of 5% perchloric acid was added, and the tablets were extracted by shaking for 10 minutes. The volume was adjusted to 200 mL with water and ultrasonicated for 10 minutes. After filtration, the tablets were subjected to high performance liquid chromatography (HPLC). <HPLC Operating Conditions> Model: LC-20AD, Shimadzu Corporation Detector: UV-Visible Absorption Photometer SPD-20AV, Shimadzu Corporation Column: Shim-pack SCR-102H 300×80 (length × inner diameter (mm)) Shimadzu Corporation Column Temperature: 40°C Mobile Phase: 3 mmol / L Perchloric Acid Reaction Solution: Containing 0.2 mmol / L Bromothymol Blue 15 mmol / L Disodium Hydrogen Phosphate Solution Flow Rate: Mobile Phase 1.0 mL / min, Reaction Solution 1.4 mL / min Measurement Wavelength: 445 nm

[0044] [Analysis of Cellulose] After collecting 0.5 - 10 g of effervescent oral tablets in a 250 mL centrifuge tube, 85 mL of 0.05% sodium chloride aqueous solution was added. The mixture was heat-treated in a boiling water bath for 30 minutes and then quickly cooled. After adding 5 mL of pancreatin solution to the cooled liquid, it was incubated in an environment of pH 6.5 and 40°C for 16 hours. The incubated liquid was centrifuged, and the solid matter was collected using filter paper (ADVANTEC 101). 50 mL of 5% sulfuric acid aqueous solution was added to the collected residue and left in a boiling water bath for 2.5 hours. Then, the solution was suction-filtered using a glass filter (1G3), and the residue was washed with acetone and diethyl ether. Further, 30 mL of 72% sulfuric acid was added to the washed solid matter, left in a refrigerator at 5°C for 24 hours or more, and then suction-filtered. The amount of glucose in the filtrate was measured using the phenol-sulfuric acid method to quantify the amount of cellulose.

[0045] Each component was mixed with the formulation compositions described in Tables 1 - 4. Next, using a single-punch tableting machine (RIKEN) and a ring-shaped punch with a hole diameter of 15 mm, tableting was performed at a tableting pressure of 18 MPa to obtain circular tablets with a tablet weight of 1 g / tablet and a diameter of 15 mm. Regarding the tablets, evaluations were conducted on the ease of swallowing, bitterness derived from carbonates, foaming sensation, and swelling of the container according to the following method.

[0046] [Melting in the mouth] Three expert panelists evaluated the melting of one tablet obtained in each example when it was placed in the mouth. The evaluation criteria were as follows, and the average score of the expert panelists was calculated and rounded off to the nearest tenth to determine the score. Example 3, in which the tablet melted slowly and felt the best in the mouth when taken, was given an evaluation criterion of 4, and Comparative Example 3, in which the tablet melted poorly in the mouth when taken, was given an evaluation criterion of 1. 4: Melts in your mouth very well 3: Melts easily in the mouth 2: Melts in the mouth rather well 1: Doesn't melt in the mouth

[0047] 〔bitter taste〕 Three expert panelists evaluated the bitterness derived from carbonate when one tablet obtained in each example was put in the mouth. The evaluation criteria were as follows, and the average score of the expert panelists was calculated and rounded off to the nearest tenth to determine the score. The three expert panelists rated Example 3, which had no bitterness at all when taken, as 4 on the evaluation criteria, and Comparative Example 1, which had a strong bitterness when taken, as 1 on the evaluation criteria. 4: No bitterness at all 3: Slightly bitter taste 2: Tastes bitter 1: Strong bitterness

[0048] [Foaminess] Three expert panelists evaluated the effervescence of each tablet when it was placed in the mouth. The evaluation results were determined by calculating the average score of the expert panelists and rounding off to the nearest tenth. Example 2, which is highly foamed and gives a fairly strong, pleasant effervescence when taken, was given an evaluation standard of 4, while Comparative Example 2, which does not give a very pleasant effervescence when taken, was given an evaluation standard of 1. 4: I feel a pleasant, strong effervescence. 3: A strong, pleasant effervescence 2: A pleasant, slightly effervescent sensation 1: I don't really feel a pleasant fizz.

[0049] [Container swelling] Each tablet was placed in an aluminum pillow (60 mm x 60 mm), sealed, and stored in a thermostatic chamber at 60°C for one week. The volume of the pillow before and after storage was measured by Archimedes' method, and the change in volume of the pillow before and after storage was calculated. The evaluation criteria were as follows, and a score was determined. 4: Swelling volume is less than 7mL 3: Swelling volume is 7mL or more but less than 9mL 2: Swelling volume is 9mL or more but less than 10mL 1: Swelling volume is 10mL or more

[0050] [Raw materials] Sodium bicarbonate: baking soda (food additive C) (Tosoh Corporation) Citric acid: Fuso citrate (anhydrous) (Fuso Chemical Co., Ltd.) Ascorbic acid: Vitamin C type SS (Fuso Chemical Co., Ltd.) Malic acid: Fuso Malic Acid (Fuso Chemical Co., Ltd.) Tartaric acid: L-tartaric acid type SS (Fuso Chemical Industry Co., Ltd.) Powdered cellulose: KC-Flock W-100G (Nippon Paper Industries Co., Ltd.), average particle size 37 μm, L / D = 2.8 Crystalline cellulose: Ceolas ST-100 (Asahi Kasei Corporation), average particle size 50 μm, L / D=3.5 Powdered cellulose: KC-Flock W-400G (Nippon Paper Industries Co., Ltd.), average particle size 24 μm, L / D=2.1 Crystalline cellulose: Ceolas UF-F702 (Asahi Kasei Corporation), average particle size 90 μm, L / D=4.8 Maltitol: Amalti MR-50 (Mitsubishi Corporation Foodtech Co., Ltd.) Calcium stearate: Calcium stearate (Taihei Chemical Co., Ltd.) Silicon dioxide: Carplex FPS-500 (EVONIK)

[0051] [Table 1]

[0052] [Table 2]

[0053] [Table 3]

[0054] [Table 4] From Tables 1 to 4, it can be seen that by ensuring that the ratio of component (C) to component (A) is within a specific range and that the ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups (mol) of component (B) is within a specific range, a product can have a pleasant high foaming sensation in the mouth, good melt-in-the-mouth feel, and good flavor, and can also suppress swelling when sealed in a container.

Claims

1. The following components (A), (B) and (C): (A) Carbonate 14 to 30 mass% (B) Organic acid or its salt (C) Cellulose having an average particle size of 30 to 70 μm: 0.5 to 50% by mass a ratio of the number of moles (mol) of component (A) to the number of moles (mol) of acid groups of component (B) [number of moles (mol) of (A) / number of moles (mol) of acid groups of (B)] is 0.25 or more and 3.0 or less, and a mass ratio of component (A) to component (C) [(A) / (C)] is 0.5 or more.

2. 2. The effervescent tablet for oral administration in a sealed container according to claim 1, wherein component (B) contains one or more members selected from the group consisting of hydroxycarboxylic acids, ascorbic acid and salts thereof.

3. 3. The effervescent oral tablet in a sealed container according to claim 1 or 2, which is a troche tablet.

4. The effervescent oral tablet in a sealed container according to any one of claims 1 to 3, further comprising a sugar alcohol.

5. The effervescent oral tablet in a sealed container according to any one of claims 1 to 4, wherein the content of oligosaccharides is 10% by mass or less.

Citation Information

Patent Citations

  • Ibuprofen rapidly disintegrating tablet in oral cavity for pain treatment and preparing method thereof

    CN101032472A

  • Drug composition

    JP1987135418A

  • Solid pharmaceutical for oral use

    JP1992327526A

  • Composition for replenishing oligosaccharide

    JP2001008666A

  • Candy

    JP2004016073A